

SEQUENCE LISTING

<110> Tomizawa, Kazuhito

Matsui, Hideki

<120> Inhibitor of constitutive active forming of carcineurin

<130> JP-13650

<160> 6

<210> 1

<211> 16

<212> PRT

<213> human

<400> 1

Phe Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys

1

5

10

15

<210> 2

<211> 17

<212> PRT

<213> human

<400> 2

Arg Glu Glu Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr

1

5

10

15

Gly

<210> 3

<211> 521

<212> PRT

<213> human

<400> 3

Met	Ser	Glu	Pro	Lys	Ala	Ile	Asp	Pro	Lys	Leu	Ser	Thr	Thr	Asp	Arg
1				5					10					15	

Val	Val	Lys	Ala	Val	Pro	Phe	Pro	Pro	Ser	His	Arg	Leu	Thr	Ala	Lys
			20					25					30		

Glu	Val	Phe	Asp	Asn	Asp	Gly	Lys	Pro	Arg	Val	Asp	Ile	Leu	Lys	Ala
		35					40					45			

His	Leu	Met	Lys	Glu	Gly	Arg	Leu	Glu	Glu	Ser	Val	Ala	Leu	Arg	Ile
	50					55					60				

Ile	Thr	Glu	Gly	Ala	Ser	Ile	Leu	Arg	Gln	Glu	Lys	Asn	Leu	Leu	Asp
65					70					75				80	

Ile	Asp	Ala	Pro	Val	Thr	Val	Cys	Gly	Asp	Ile	His	Gly	Gln	Phe	Phe
				85						90				95	

Asp	Leu	Met	Lys	Leu	Phe	Glu	Val	Gly	Gly	Ser	Pro	Ala	Asn	Thr	Arg
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

100	105	110
Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Tyr Phe Ser Ile Glu		
115	120	125
Cys Val Leu Tyr Leu Trp Ala Leu Lys Ile Leu Tyr Pro Lys Thr Leu		
130	135	140
Phe Leu Leu Arg Gly Asn His Glu Cys Arg His Leu Thr Glu Tyr Phe		
145	150	155
		160
Thr Phe Lys Gln Glu Cys Lys Ile Lys Tyr Ser Glu Arg Val Tyr Asp		
165	170	175
Ala Cys Met Asp Ala Phe Asp Cys Leu Pro Leu Ala Ala Leu Met Asn		
180	185	190
Gln Gln Phe Leu Cys Val His Gly Gly Leu Ser Pro Glu Ile Asn Thr		
195	200	205
Leu Asp Asp Ile Arg Lys Leu Asp Arg Phe Lys Glu Pro Pro Ala Tyr		
210	215	220
Gly Pro Met Cys Asp Ile Leu Trp Ser Asp Pro Leu Glu Asp Phe Gly		
225	230	235
		240
Asn Glu Lys Thr Gln Glu His Phe Thr His Asn Thr Val Arg Gly Cys		
245	250	255

Ser Tyr Phe Tyr Ser Tyr Pro Ala Val Cys Asp Phe Leu Gln His Asn
 260 265 270

Asn Leu Leu Ser Ile Leu Arg Ala His Glu Ala Gln Asp Ala Gly Tyr
 275 280 285

Arg Met Tyr Arg Lys Ser Gln Thr Thr Gly Phe Pro Ser Leu Ile Thr
 290 295 300

Ile Phe Ser Ala Pro Asn Tyr Leu Asp Val Tyr Asn Asn Lys Ala Ala
 305 310 315 320

Val Leu Lys Tyr Glu Asn Asn Val Met Asn Ile Arg Gln Phe Asn Cys
 325 330 335

Ser Pro His Pro Tyr Trp Leu Pro Asn Phe Met Asp Val Phe Thr Trp
 340 345 350

Ser Leu Pro Phe Val Gly Glu Lys Val Thr Glu Met Leu Val Asn Val
 355 360 365

Leu Asn Ile Cys Ser Asp Asp Glu Leu Gly Ser Glu Glu Asp Gly Phe
 370 375 380

Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys Ile
 385 390 395 400

Arg Ala Ile Gly Lys Met Ala Arg Val Phe Ser Val Leu Arg Glu Glu
 405 410 415

Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly Met Leu
 420 425 430

Pro Ser Gly Val Leu Ser Gly Gly Lys Gln Thr Leu Gln Ser Ala Thr
 435 440 445

Val Glu Ala Ile Glu Ala Asp Glu Ala Ile Lys Gly Phe Ser Pro Gln
 450 455 460

His Lys Ile Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg Ile Asn
 465 470 475 480

Glu Arg Met Pro Pro Arg Arg Asp Ala Met Pro Ser Asp Ala Asn Leu
 485 490 495

Asn Ser Ile Asn Lys Ala Leu Ala Ser Glu Thr Asn Gly Thr Asp Ser
 500 505 510

Asn Gly Ser Asn Ser Ser Asn Ile Gln
 515 520

<210> 4

<211> 11

<212> PRT

<213> HIV virus

<400> 4

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg

1 5 10

<210> 5

<211> 26

<212> PRT

<213> human

<400> 5

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Phe Asp Gly Ala Thr Ala

1 5 10 15

Ala Ala Arg Lys Glu Val Ile Arg Asn Lys

20 25

<210> 6

<211> 27

<212> PRT

<213> human

<400> 6

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Glu Glu Ser Glu Ser

1 5 10 15

Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly

20

25